Eckelman Brendan P.
Officer at Inhibrx, Inc.
- Sold, on record
- $17.2M
- Dollars the filings state
- Form 4 sales
- 9
- Latest May 28, 2024
- Form 144 notices
- 6
- Proposed sales
- Companies
- 1
- Filed as an executive or holder
Companies
- Inhibrx, Inc.Officer
Sales by reason
Form 4 sales per month, last 12 months.
Timeline
- 1 Form 4 sale Inhibrx, Inc.Plan not statedFeb 2 2023
Sold 40,000 shares at $24.93 ($997k)
Eckelman Brendan P., Chief Scientific Officer
Sold 1.9% of holdings ($52.7M position)2.1M shares left1x usual sizeFiling
- 2 Form 144 notice Inhibrx, Inc.NoticeMar 8 +400 days
Filed to sell 2,150 shares ($77k)
Eckelman Brendan P., Officer
No 10b5-1 plan0.1x usual sizeFiling
- 3 Form 144 notice Inhibrx, Inc.NoticeMar 11 +3 days
Filed to sell 13,558 shares ($479k)
Eckelman Brendan P., Officer
No 10b5-1 plan0.3x usual sizeFiling
- 4 Form 144 notice Inhibrx, Inc.NoticeMar 12 +1 day
Filed to sell 24,050 shares ($848k)
Eckelman Brendan P., Officer
No 10b5-1 plan0.6x usual sizeFiling
- 5 Form 144 notice Inhibrx, Inc.NoticeMar 13 +1 day
Filed to sell 1,898 shares ($67k)
Eckelman Brendan P., Officer
No 10b5-1 plan0x usual sizeFiling
- 6 Form 144 notice Inhibrx, Inc.NoticeMay 22 +70 days
Filed to sell 5,010 shares ($171k)
Eckelman Brendan P., Officer
No 10b5-1 plan0.1x usual sizeFiling
- 7 Form 144 notice Inhibrx, Inc.NoticeMay 28 +6 days
Filed to sell 300,000 shares ($10.3M)
Eckelman Brendan P., Officer
No 10b5-1 plan7.5x usual sizeFiling
- 8 Form 4 sale Inhibrx, Inc.UnusualMay 28 same day
Sold 300,000 shares at $34.30 ($10.3M)
Eckelman Brendan P., Chief Scientific Officer
No 10b5-1 planSold 14.7% of holdings ($69.8M position)1.7M shares left7.5x usual sizeFollows a Form 144Filing
Every transaction
Loading transactions…
Sales and notices (15)
| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| May 28, 2024 | Inhibrx, Inc. | Chief Scientific Officer | Form 4 sale | 300,000 | $10.3M | 14.7% | Unusual | SEC |
| May 28, 2024 | Inhibrx, Inc. | Officer | Form 144 notice | 300,000 | $10.3M | Notice | SEC | |
| May 22, 2024 | Inhibrx, Inc. | Officer | Form 144 notice | 5,010 | $171k | Notice | SEC | |
| Mar 13, 2024 | Inhibrx, Inc. | Officer | Form 144 notice | 1,898 | $67k | Notice | SEC | |
| Mar 12, 2024 | Inhibrx, Inc. | Officer | Form 144 notice | 24,050 | $848k | Notice | SEC | |
| Mar 11, 2024 | Inhibrx, Inc. | Officer | Form 144 notice | 13,558 | $479k | Notice | SEC | |
| Mar 8, 2024 | Inhibrx, Inc. | Officer | Form 144 notice | 2,150 | $77k | Notice | SEC | |
| Feb 2, 2023 | Inhibrx, Inc. | Chief Scientific Officer | Form 4 sale | 40,000 | $997k | 1.9% | Plan not stated | SEC |
| Dec 6, 2022 | Inhibrx, Inc. | Chief Scientific Officer | Form 4 sale | 40,000 | $1.1M | 1.8% | Plan not stated | SEC |
| Nov 1, 2022 | Inhibrx, Inc. | Chief Scientific Officer | Form 4 sale | 40,000 | $1.3M | 1.8% | Plan not stated | SEC |
| Oct 4, 2022 | Inhibrx, Inc. | Chief Scientific Officer | Form 4 sale | 40,000 | $1.1M | 1.8% | Plan not stated | SEC |
| Sep 6, 2022 | Inhibrx, Inc. | Chief Scientific Officer | Form 4 sale | 40,000 | $596k | 1.6% | Plan not stated | SEC |
| Aug 3, 2022 | Inhibrx, Inc. | Chief Scientific Officer | Form 4 sale | 40,000 | $720k | 1.6% | Plan not stated | SEC |
| Jul 7, 2022 | Inhibrx, Inc. | Chief Scientific Officer | Form 4 sale | 40,000 | $687k | 1.6% | Plan not stated | SEC |
| Mar 24, 2021 | Inhibrx, Inc. | Chief Scientific Officer | Form 4 sale | 17,000 | $323k | 0.7% | Plan not stated | SEC |